Management ChangeNov 10, 2026, 05:41 PM
Spero Therapeutics Appoints William Ho to Board, Patrick Vink Resigns
AI Summary
Spero Therapeutics, Inc. announced changes to its Board of Directors. Patrick Vink resigned as a Class II director and committee member, effective November 10, 2026. The company appointed William Ho as a new Class II director, filling the vacancy left by Dr. Vink. Dr. Ho also joined the Development Committee and will receive a cash retainer and stock options as compensation.
Key Highlights
- Patrick Vink resigns as Class II director and Chair of Nominating and Corporate Governance Committee.
- William Ho appointed as Class II director and member of the Development Committee.
- Dr. Ho to receive $40,000 annual retainer for Board service and $5,000 for committee service.
- Dr. Ho granted an option to purchase 100,000 shares of common stock, vesting over one year.
Price Impact
More from SPRO